Modulation of the Tryptophan Hydroxylase 1/Monoamine Oxidase-A/5-Hydroxytryptamine/5-Hydroxytryptamine Receptor 2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis

Konstantina Kyritsi, Lixian Chen, April O'Brien, Heather Francis, Travis W. Hein, Julie Venter, Nan Wu, Ludovica Ceci, Tianhao Zhou, David Zawieja, Anatoliy A. Gashev, Fanyin Meng, Pietro Invernizzi, Luca Fabris, Chaodong Wu, Nicholas J. Skill, Romil Saxena, Suthat Liangpunsakul, Gianfranco Alpini, Shannon S. Glaser

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background and Aims: Serotonin (5HT) is a neuroendocrine hormone synthetized in the central nervous system (CNS) as well as enterochromaffin cells of the gastrointestinal tract. Tryptophan hydroxylase (TPH1) and monoamine oxidase (MAO-A) are the key enzymes for the synthesis and catabolism of 5HT, respectively. Previous studies demonstrated that 5-hydroxytryptamine receptor (5HTR)1A/1B receptor agonists inhibit biliary hyperplasia in bile-duct ligated (BDL) rats, whereas 5HTR2B receptor antagonists attenuate liver fibrosis (LF) in mice. Our aim was to evaluate the role of 5HTR2A/2B/2C agonists/antagonists in cholestatic models. Approach and Results: While in vivo studies were performed in BDL rats and the multidrug resistance gene 2 knockout (Mdr2–/–) mouse model of PSC, in vitro studies were performed in cell lines of cholangiocytes and hepatic stellate cells (HSCs). 5HTR2A/2B/2C and MAO-A/TPH1 are expressed in cholangiocytes and HSCs from BDL rats and Mdr2–/– - mice. Ductular reaction, LF, as well as the mRNA expression of proinflammatory genes increased in normal, BDL rats, and Mdr2–/– - mice following treatment 5HTR2A/2B/2C agonists, but decreased when BDL rats and Mdr2–/– mice were treated with 5HTR2A/2B/2C antagonists compared to BDL rats and Mdr2–/– mice, respectively. 5HT levels increase in Mdr2–/– mice and in PSC human patients compared to their controls and decrease in serum of Mdr2–/– mice treated with 5HTR2A/2B/2C antagonists compared to untreated Mdr2–/– mice. In vitro, cell lines of murine cholangiocytes and human HSCs express 5HTR2A/2B/2C and MAO-A/TPH1; treatment of these cell lines with 5HTR2A/2B/2C antagonists or TPH1 inhibitor decreased 5HT levels as well as expression of fibrosis and inflammation genes compared to controls. Conclusions: Modulation of the TPH1/MAO-A/5HT/5HTR2A/2B/2C axis may represent a therapeutic approach for management of cholangiopathies, including PSC.

Original languageEnglish (US)
JournalHepatology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Tryptophan Hydroxylase
Serotonin Receptors
Cholestasis
Monoamine Oxidase
Liver Cirrhosis
Bile Ducts
Hepatic Stellate Cells
Cell Line
Enterochromaffin Cells
Receptor, Serotonin, 5-HT1B
MDR Genes
Gene Knockout Techniques
Receptor, Serotonin, 5-HT1A
serotonin 5 receptor
Knockout Mice
Hyperplasia
Gastrointestinal Tract
Serotonin
Fibrosis
Therapeutics

ASJC Scopus subject areas

  • Hepatology

Cite this

Modulation of the Tryptophan Hydroxylase 1/Monoamine Oxidase-A/5-Hydroxytryptamine/5-Hydroxytryptamine Receptor 2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis. / Kyritsi, Konstantina; Chen, Lixian; O'Brien, April; Francis, Heather; Hein, Travis W.; Venter, Julie; Wu, Nan; Ceci, Ludovica; Zhou, Tianhao; Zawieja, David; Gashev, Anatoliy A.; Meng, Fanyin; Invernizzi, Pietro; Fabris, Luca; Wu, Chaodong; Skill, Nicholas J.; Saxena, Romil; Liangpunsakul, Suthat; Alpini, Gianfranco; Glaser, Shannon S.

In: Hepatology, 01.01.2019.

Research output: Contribution to journalArticle

Kyritsi, K, Chen, L, O'Brien, A, Francis, H, Hein, TW, Venter, J, Wu, N, Ceci, L, Zhou, T, Zawieja, D, Gashev, AA, Meng, F, Invernizzi, P, Fabris, L, Wu, C, Skill, NJ, Saxena, R, Liangpunsakul, S, Alpini, G & Glaser, SS 2019, 'Modulation of the Tryptophan Hydroxylase 1/Monoamine Oxidase-A/5-Hydroxytryptamine/5-Hydroxytryptamine Receptor 2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis', Hepatology. https://doi.org/10.1002/hep.30880
Kyritsi, Konstantina ; Chen, Lixian ; O'Brien, April ; Francis, Heather ; Hein, Travis W. ; Venter, Julie ; Wu, Nan ; Ceci, Ludovica ; Zhou, Tianhao ; Zawieja, David ; Gashev, Anatoliy A. ; Meng, Fanyin ; Invernizzi, Pietro ; Fabris, Luca ; Wu, Chaodong ; Skill, Nicholas J. ; Saxena, Romil ; Liangpunsakul, Suthat ; Alpini, Gianfranco ; Glaser, Shannon S. / Modulation of the Tryptophan Hydroxylase 1/Monoamine Oxidase-A/5-Hydroxytryptamine/5-Hydroxytryptamine Receptor 2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis. In: Hepatology. 2019.
@article{c787b5b0347c444ba2608d3ec52b6827,
title = "Modulation of the Tryptophan Hydroxylase 1/Monoamine Oxidase-A/5-Hydroxytryptamine/5-Hydroxytryptamine Receptor 2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis",
abstract = "Background and Aims: Serotonin (5HT) is a neuroendocrine hormone synthetized in the central nervous system (CNS) as well as enterochromaffin cells of the gastrointestinal tract. Tryptophan hydroxylase (TPH1) and monoamine oxidase (MAO-A) are the key enzymes for the synthesis and catabolism of 5HT, respectively. Previous studies demonstrated that 5-hydroxytryptamine receptor (5HTR)1A/1B receptor agonists inhibit biliary hyperplasia in bile-duct ligated (BDL) rats, whereas 5HTR2B receptor antagonists attenuate liver fibrosis (LF) in mice. Our aim was to evaluate the role of 5HTR2A/2B/2C agonists/antagonists in cholestatic models. Approach and Results: While in vivo studies were performed in BDL rats and the multidrug resistance gene 2 knockout (Mdr2–/–) mouse model of PSC, in vitro studies were performed in cell lines of cholangiocytes and hepatic stellate cells (HSCs). 5HTR2A/2B/2C and MAO-A/TPH1 are expressed in cholangiocytes and HSCs from BDL rats and Mdr2–/– - mice. Ductular reaction, LF, as well as the mRNA expression of proinflammatory genes increased in normal, BDL rats, and Mdr2–/– - mice following treatment 5HTR2A/2B/2C agonists, but decreased when BDL rats and Mdr2–/– mice were treated with 5HTR2A/2B/2C antagonists compared to BDL rats and Mdr2–/– mice, respectively. 5HT levels increase in Mdr2–/– mice and in PSC human patients compared to their controls and decrease in serum of Mdr2–/– mice treated with 5HTR2A/2B/2C antagonists compared to untreated Mdr2–/– mice. In vitro, cell lines of murine cholangiocytes and human HSCs express 5HTR2A/2B/2C and MAO-A/TPH1; treatment of these cell lines with 5HTR2A/2B/2C antagonists or TPH1 inhibitor decreased 5HT levels as well as expression of fibrosis and inflammation genes compared to controls. Conclusions: Modulation of the TPH1/MAO-A/5HT/5HTR2A/2B/2C axis may represent a therapeutic approach for management of cholangiopathies, including PSC.",
author = "Konstantina Kyritsi and Lixian Chen and April O'Brien and Heather Francis and Hein, {Travis W.} and Julie Venter and Nan Wu and Ludovica Ceci and Tianhao Zhou and David Zawieja and Gashev, {Anatoliy A.} and Fanyin Meng and Pietro Invernizzi and Luca Fabris and Chaodong Wu and Skill, {Nicholas J.} and Romil Saxena and Suthat Liangpunsakul and Gianfranco Alpini and Glaser, {Shannon S.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/hep.30880",
language = "English (US)",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Modulation of the Tryptophan Hydroxylase 1/Monoamine Oxidase-A/5-Hydroxytryptamine/5-Hydroxytryptamine Receptor 2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis

AU - Kyritsi, Konstantina

AU - Chen, Lixian

AU - O'Brien, April

AU - Francis, Heather

AU - Hein, Travis W.

AU - Venter, Julie

AU - Wu, Nan

AU - Ceci, Ludovica

AU - Zhou, Tianhao

AU - Zawieja, David

AU - Gashev, Anatoliy A.

AU - Meng, Fanyin

AU - Invernizzi, Pietro

AU - Fabris, Luca

AU - Wu, Chaodong

AU - Skill, Nicholas J.

AU - Saxena, Romil

AU - Liangpunsakul, Suthat

AU - Alpini, Gianfranco

AU - Glaser, Shannon S.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background and Aims: Serotonin (5HT) is a neuroendocrine hormone synthetized in the central nervous system (CNS) as well as enterochromaffin cells of the gastrointestinal tract. Tryptophan hydroxylase (TPH1) and monoamine oxidase (MAO-A) are the key enzymes for the synthesis and catabolism of 5HT, respectively. Previous studies demonstrated that 5-hydroxytryptamine receptor (5HTR)1A/1B receptor agonists inhibit biliary hyperplasia in bile-duct ligated (BDL) rats, whereas 5HTR2B receptor antagonists attenuate liver fibrosis (LF) in mice. Our aim was to evaluate the role of 5HTR2A/2B/2C agonists/antagonists in cholestatic models. Approach and Results: While in vivo studies were performed in BDL rats and the multidrug resistance gene 2 knockout (Mdr2–/–) mouse model of PSC, in vitro studies were performed in cell lines of cholangiocytes and hepatic stellate cells (HSCs). 5HTR2A/2B/2C and MAO-A/TPH1 are expressed in cholangiocytes and HSCs from BDL rats and Mdr2–/– - mice. Ductular reaction, LF, as well as the mRNA expression of proinflammatory genes increased in normal, BDL rats, and Mdr2–/– - mice following treatment 5HTR2A/2B/2C agonists, but decreased when BDL rats and Mdr2–/– mice were treated with 5HTR2A/2B/2C antagonists compared to BDL rats and Mdr2–/– mice, respectively. 5HT levels increase in Mdr2–/– mice and in PSC human patients compared to their controls and decrease in serum of Mdr2–/– mice treated with 5HTR2A/2B/2C antagonists compared to untreated Mdr2–/– mice. In vitro, cell lines of murine cholangiocytes and human HSCs express 5HTR2A/2B/2C and MAO-A/TPH1; treatment of these cell lines with 5HTR2A/2B/2C antagonists or TPH1 inhibitor decreased 5HT levels as well as expression of fibrosis and inflammation genes compared to controls. Conclusions: Modulation of the TPH1/MAO-A/5HT/5HTR2A/2B/2C axis may represent a therapeutic approach for management of cholangiopathies, including PSC.

AB - Background and Aims: Serotonin (5HT) is a neuroendocrine hormone synthetized in the central nervous system (CNS) as well as enterochromaffin cells of the gastrointestinal tract. Tryptophan hydroxylase (TPH1) and monoamine oxidase (MAO-A) are the key enzymes for the synthesis and catabolism of 5HT, respectively. Previous studies demonstrated that 5-hydroxytryptamine receptor (5HTR)1A/1B receptor agonists inhibit biliary hyperplasia in bile-duct ligated (BDL) rats, whereas 5HTR2B receptor antagonists attenuate liver fibrosis (LF) in mice. Our aim was to evaluate the role of 5HTR2A/2B/2C agonists/antagonists in cholestatic models. Approach and Results: While in vivo studies were performed in BDL rats and the multidrug resistance gene 2 knockout (Mdr2–/–) mouse model of PSC, in vitro studies were performed in cell lines of cholangiocytes and hepatic stellate cells (HSCs). 5HTR2A/2B/2C and MAO-A/TPH1 are expressed in cholangiocytes and HSCs from BDL rats and Mdr2–/– - mice. Ductular reaction, LF, as well as the mRNA expression of proinflammatory genes increased in normal, BDL rats, and Mdr2–/– - mice following treatment 5HTR2A/2B/2C agonists, but decreased when BDL rats and Mdr2–/– mice were treated with 5HTR2A/2B/2C antagonists compared to BDL rats and Mdr2–/– mice, respectively. 5HT levels increase in Mdr2–/– mice and in PSC human patients compared to their controls and decrease in serum of Mdr2–/– mice treated with 5HTR2A/2B/2C antagonists compared to untreated Mdr2–/– mice. In vitro, cell lines of murine cholangiocytes and human HSCs express 5HTR2A/2B/2C and MAO-A/TPH1; treatment of these cell lines with 5HTR2A/2B/2C antagonists or TPH1 inhibitor decreased 5HT levels as well as expression of fibrosis and inflammation genes compared to controls. Conclusions: Modulation of the TPH1/MAO-A/5HT/5HTR2A/2B/2C axis may represent a therapeutic approach for management of cholangiopathies, including PSC.

UR - http://www.scopus.com/inward/record.url?scp=85074278372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074278372&partnerID=8YFLogxK

U2 - 10.1002/hep.30880

DO - 10.1002/hep.30880

M3 - Article

C2 - 31344280

AN - SCOPUS:85074278372

JO - Hepatology

JF - Hepatology

SN - 0270-9139

ER -